Cerebral Amyloid and Hypertension are Independently Associated with White Matter Lesions in Elderly
暂无分享,去创建一个
Paul M. Thompson | Owen T. Carmichael | Charles DeCarli | Meredith N. Braskie | Michael Weiner | Julia A. Scott | Duygu Tosun | Owen Carmichael | C. DeCarli | M. Weiner | P. Thompson | M. Braskie | D. Tosun | P. Thompson | P. Thompson
[1] Carole Dufouil,et al. Antihypertensive Treatment and Change in Blood Pressure Are Associated With the Progression of White Matter Lesion Volumes: The Three-City (3C)–Dijon Magnetic Resonance Imaging Study , 2011, Circulation.
[2] Klaus P. Ebmeier,et al. Lifetime hypertension as a predictor of brain structure in older adults: cohort study with a 28-year follow-up , 2015, British Journal of Psychiatry.
[3] C. DeCarli,et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline , 2011, Alzheimer's & Dementia.
[4] J. Schneider,et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease , 2015, Alzheimer's & Dementia.
[5] F. Fazekas,et al. Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. , 1996, Stroke.
[6] P. Wolf,et al. Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. , 2009, Stroke.
[7] Vijay K. Venkatraman,et al. Longitudinal Systolic Blood Pressure Characteristics and Integrity of White Matter Tracts in a Cohort of Very Old Black and White Adults , 2014, American Journal of Hypertension.
[8] A. Joutel,et al. Early white matter changes in CADASIL: evidence of segmental intramyelinic oedema in a pre-clinical mouse model , 2014, Acta neuropathologica communications.
[9] Wiro J Niessen,et al. High Blood Pressure and Cerebral White Matter Lesion Progression in the General Population , 2013, Hypertension.
[10] B. Mazoyer,et al. Plasma &bgr;-amyloid and MRI markers of cerebral small vessel disease: Three-City Dijon Study , 2014, Neurology.
[11] M. Pencina,et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.
[12] A. Hofman,et al. Determinants, MRI correlates, and prognosis of mild cognitive impairment: the Rotterdam Study. , 2014, Journal of Alzheimer's disease : JAD.
[13] M. Mintun,et al. Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.
[14] J. Morris,et al. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.
[15] M. Woodward,et al. Effects of Blood Pressure Lowering on Cerebral White Matter Hyperintensities in Patients With Stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy , 2005, Circulation.
[16] R. Sacco,et al. Lipid Profile Components and Subclinical Cerebrovascular Disease in the Northern Manhattan Study , 2014, Cerebrovascular Diseases.
[17] Nick C Fox,et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration , 2013, The Lancet Neurology.
[18] P. Scheltens,et al. Dementia: Alzheimer pathology and vascular factors: from mutually exclusive to interaction. , 2012, Biochimica et biophysica acta.
[19] M. Carrillo,et al. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective , 2015, Alzheimer's & Dementia.
[20] A Hofman,et al. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study , 1993, The Lancet.
[21] Owen Carmichael,et al. Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage. , 2013, Psychology and aging.
[22] Owen Carmichael,et al. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. , 2010, Archives of neurology.
[23] Robert A. Dean,et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI , 2011, Acta Neuropathologica.
[24] A. Brickman. Contemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities , 2013, Current Neurology and Neuroscience Reports.
[25] O. Levin,et al. [Cerebral amyloid angiopathy]. , 2014, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
[26] W. M. van der Flier,et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[27] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[28] J. Meulman,et al. Prediction accuracy and stability of regression optimal scaling transformations , 1996 .
[29] W. W. Muir,et al. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity , 1980 .
[30] W. Jagust,et al. Vascular burden and Alzheimer disease pathologic progression , 2012, Neurology.
[31] A Hofman,et al. A follow‐up study of blood pressure and cerebral white matter lesions , 1999, Annals of neurology.
[32] L. Launer,et al. Lowering Midlife Levels of Systolic Blood Pressure as a Public Health Strategy to Reduce Late-Life Dementia: Perspective From the Honolulu Heart Program/Honolulu Asia Aging Study , 2010, Hypertension.
[33] Nick C. Fox,et al. Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls , 2013, Neurobiology of Aging.
[34] Paul Maruff,et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.
[35] J. Becker,et al. Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[36] G. Biessels,et al. Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. , 2015, The lancet. Diabetes & endocrinology.
[37] S. D. Preston,et al. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid β from the human brain , 2003, Neuropathology and applied neurobiology.
[38] A. Wallin,et al. Associations between white matter lesions, cerebrovascular risk factors, and low CSF Aβ42 , 2006, Neurology.
[39] M. Mullan,et al. β-Amyloid-mediated vasoactivity and vascular endothelial damage , 1996, Nature.
[40] Masanori Ichise,et al. Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated , 2015, Neuroscience Letters.
[41] Thaddeus J. Haight,et al. Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. , 2013, JAMA neurology.
[42] OphéliaGodin,et al. Antihypertensive Treatment and Change in Blood Pressure Are Associated With the Progression of White Matter Lesion Volumes , 2011 .
[43] Sandra Black,et al. Understanding White Matter Disease: Imaging-Pathological Correlations in Vascular Cognitive Impairment , 2009, Stroke.
[44] Owen T. Carmichael,et al. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment , 2013, Alzheimer's & Dementia.
[45] C. DeCarli,et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology , 1998, Neurology.
[46] Jordan Muraskin,et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? , 2013, JAMA neurology.
[47] M. Mullan,et al. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. , 1996, Nature.
[48] D. Harvey,et al. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD , 2006, Neurology.
[49] C. Wright,et al. Vascular contributions to cognitive impairment. , 2015, Neurology. Clinical practice.